Astrana Health Inc 2024年度报告

(Mark One)☐ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2024OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934for the transition period from___ to ___.Commission file number: 001-37392 Astrana Health, Inc. (Exact name of registrant as specified in its charter) Common Stock, $0.001 par value per shareASTHThe Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the SecuritiesAct. Yes☐No☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) ofthe Exchange Act. Yes☐No☐ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that theregistrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90days. Yes☐No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required tobe submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months(or for such shorter period that the registrant was required to submit such files). Yes☐No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, a smaller reporting company, or an emerging growth company. See the definitions of “large acceleratedfiler,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of theExchange Act. Large accelerated filerNon-accelerated filer ☐Accelerated filer☐Smaller reporting companyEmerging growth company ☐☐☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransition period for complying with any new or revised financial accounting standards provided pursuant toSection 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’sassessment of the effectiveness of its internal control over financial reporting under Section 404(b) of theSarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its auditreport.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financialstatements of the registrant included in the filing reflect the correction of an error to previously issued financialstatements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysisof incentive-based compensation received by any of the registrant’s executive officers during the relevantrecovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).☐Yes☐No The aggregate market value of common stock held by non-affiliates of the registrant, as of June 28, 2024, the lastday of the registrant’s most recently completed second fiscal quarter, was approximately $1.7 billion (based onthe closing price for shares of the registrant’s common stock as reported by the Nasdaq Stock Market on June 28,2024). As of March 6, 2025, there were 56,252,503 shares of common stock of the registrant, $0.001 par value per share,issued and outstanding, which includes 6,132,802 treasury shares that are owned by Allied Physicians ofCalifornia, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (“APC”), a consolidatedaffiliate of Astrana Health, Inc. These shares are legally issued and outstanding but treated as treasury shares foraccounting purposes. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive Proxy Statement for the 2025 annual meeting of the stockholders of theregistrant are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent statedherein. Such Proxy Statement will be filed with the Securities and Exchange Commission (the “SEC”) within 120days of the registrant’s fiscal year ended December 31, 2024. Astrana Health, Inc.Form 10-KFiscal Year Ended December 31, 2024 Table of Contents PageITEMIntroductory Note4Note About Forward-Looking Statements5 PART I6ITEM 1Business6ITEM1ARisk Factors26ITEM1BUnresolved Staff Comments62ITEM1CCybersecurity62ITEM 2Properties64ITEM 3Legal Proceedings64ITEM 4Mine Safety Disclosures64PART II65ITEM 5Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases ofEquity Securities65ITEM 6[Reserved]66ITEM 7Management’s Discussion and Analysis of Financial Condition and Results of Operations67ITEM7AQuantitative and Qualitative Disclosures About Mark